ArticleFrontiers in pediatrics2026
Clinical significance of serum brain-derived neurotrophic factor and serotonin levels in children with tic disorders.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Tic disorders (TD) are diagnosed mainly through clinical observation, and accessible peripheral biomarkers that reflect neurobiological alterations remain limited. Brain-derived neurotrophic factor (BDNF) and serotonin (5-HT) are biologically relevant to synaptic plasticity and neurochemical regulation. This study aimed to investigate serum BDNF and 5-HT levels in children with TD and to explore their associations with disease severity and clinical subtypes. Methods: A total of 125 children with TD and 100 age- and sex-matched healthy controls were enrolled. Serum BDNF and 5-HT concentrations were measured using enzyme-linked immunosorbent assay (ELISA). TD patients were further classified into mild and moderate-to-severe groups according to the Yale Global Tic Severity Scale. Biomarker differences across severity strata and TD subtypes were analyzed, and diagnostic performance was assessed using receiver operating characteristic (ROC) curves and logistic regression. Results: Serum BDNF levels were significantly lower in TD patients than in healthy controls and declined further in moderate-to-severe cases. In contrast, serum 5-HT levels did not differ between mild TD and HC but were significantly reduced in moderate-to-severe TD compared with mild cases. ROC analysis showed that BDNF (AUC 0.705, 95% CI 0.637-0.772) had modest discriminative ability for identifying TD and both BDNF (AUC 0.760, 95% CI 0.678-0.842) and 5-HT (AUC 0.652, 95% CI 0.555-0.749) were useful in distinguishing disease severity. Logistic regression identified sleep disturbances, family history of TD, and decreased BDNF were independently associated with TD. Conclusion: Reduced serum BDNF was associated with disease presence and severity, whereas decreased 5-HT was mainly related to greater symptom severity. Given the modest ROC performance, serum BDNF and 5-HT may provide auxiliary biological information for pediatric tic disorders, but their clinical application requires validation in larger multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.